(Q56970743)

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

21 January 2018

Invasive candidiasis.

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

The predictors of outcome in immunocompetent patients with hematogenous candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Risk factors for disseminated candidiasis in children with candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Early Removal of Central Venous Catheter in Patients with Candidemia Does Not Improve Outcome: Analysis of 842 Patients from 2 Randomized Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Candida biofilms on implanted biomaterials: a clinically significant problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Should central venous catheters be removed as soon as candidemia is detected in neonates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

When primary antifungal therapy fails

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Time to blood culture positivity as a marker for catheter-related candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Candida infective endocarditis: report of 15 cases from a prospective multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Candidemia in patients with ventricular assist devices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1

Risk factors and outcomes of fungal ventricular-assist device infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12281-010-0039-1